**Appendix Table D25. Randomized controlled clinical trials that examined efficacy of divalproex or valproate for migraine prevention in adults**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Active Drug** | **ReferenceSample****Number Analyzed% Women** | **Definition of Migraine% without Aura** | **Baseline Severity** | **Age of Subjects****(Eligible and Mean)** | **Years of Migraine****% with prior Preventative Treatment** |
| Divalproex | Mathew, 199545Sample 107Analyzed 105% of women 77.6 | Migraine (International Headache Society)% without aura: 95 | Days per 4 week with migraine headaches during baseline phase: 7 | 16-75Mean: 45.6 | Years of migraine: 25% with prior treatment: NR |
| Divalproex | Freitag, 200246Sample 239Analyzed 237% of women 79 | Migraine (International Headache Society)% without aura: 97 | Days per 4 week with migraine headaches during baseline phase: 6.1 | ≥12Mean: 40.5 | Years of migraine: 20.2% with prior treatment: NR |
| Divalproex | Klapper, 199747Sample 176Analyzed 171% of women 89 | Migraine (International Headache Society)% without aura: NR | Migraine attacks impairing usual activities during baseline (4 weeks): 5.8 | ≥16Mean: 40.8 | Years of migraine: 21.6% with prior treatment: 53 |
| Valproate | Hering, 199248Sample 32Analyzed 29% of women 79.3 | Migraine with aura (classical); patients suffering from migraine without aura (common); Ad Hoc Committee on Classification of Headache.% without aura: 13.7 (assumed) | From inclusion criteria: at least four attacks per months | NR (range: 18-54)Mean: 34 | Years of migraine: 14% with prior treatment: NR |
| Valproate | Jensen, 199449Sample 43Analyzed 34% of women 86 | Diagnosis of migraine without aura (International Headache Society)% without aura: 100 | Mean frequency of migraines (4 weeks): 6.6 | 18-70Mean: 46 | Years of migraine: NR% with prior treatment: NR |

NR = Not reported